108 results about "Lactobacillus crispatus" patented technology

The invention provides a naturally occurring strain of Lactobacillus crispatus with advantageous characteristics. The strain colonizes mucosal surfaces, particularly vaginal surfaces. The strain is also capable of rapid growth in a number of conditions and is highly viable after desiccation. Moreover, the strain is capable of preventing and reducing pathogenic infection of vaginal mucosa.

The present invention relates to a probiotic bacterial strain belonging to the genus Lactobacillus having the ability to colonize the human vagina, or a variant thereof. More specifically the probiotic bacterial strain belongs to a species chosen from the group comprising Lactobacillus plantarum, Lactobacillus crispatus, and Lactobacillus gasseri. Further it relates to its use as a medicament, a composition comprising the strain, the composition, e.g., being a food product or a pharmaceutical composition, a hygiene product, a biological pure culture of the strain, and a novel food.

The invention discloses a Lactobacillus crispatus 262-1 and its application in gynecological diseases. The Lactobacillus crispatus 262-1 is a new Lactobacillus crispatus strain, and has a preservation number of CGMCCNo.6469 in China General Microbiological Culture Collection Center. The Lactobacillus crispatus 262-1 has the advantages of strong acid and H2O2 production ability, strong adherence to vaginal epithelial cells, substantial resistance on bacterial vaginal diseases and various vaginal gynecological diseases, safety, non-toxicity, good stability and long term preservation. The invention also relates to a use of the Lactobacillus crispatus 262-1 in medicines for preventing and / or treating the gynecological diseases.

The invention belongs to the field of probiotics and relates to Lactobacillus crispatus SQ1505. The Lactobacillus crispatus SQ1505 has great performances of acid and hydrogen peroxide production and biofilm formation, has an adhesion effect on human vaginal epithelial cells and an antibacterial effect on vaginal pathogenic bacteria, can be used for prevention and treatment of vaginitis and is a new-generation probiotic capable of replacing antibiotics for preventing and treating female reproductive tract infections.

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The invention discloses a Lactobacillus crispatus and an application. The Lactobacillus crispatusis is preserved in the China General Microbiological Culture Collection Center (CGMCC) with accession number of CGMCC NO.6406. The Lactobacillus crispatus has high acid resistance, high-yield hydrogen peroxide characteristic and vagina pathogenic bacteria growth inhibition effect, and the invention also relates to an application of the Lactobacillus crispatus LCR15 for adjusting vaginal flora, preventing and treating colpitis.

The present invention provides a strain, which is a Lactobacillus crispatus strain and is characterized in that the preservation number is CGMCC No.6360. The present invention further provides uses of the strain in preparation of drugs for prevention and / or treatment of vaginitis, preparation of vagina care products, and preparation of external genitalia sanitary products. With the technical scheme, antagonism effects of the Lactobacillus crispatus strain on multiple pathogenic bacteria can be achieved. In addition, the strain has high adhesion to vaginal epithelial cells. The strain can well meet practical clinical application requirements.

The invention relates to active lactic acid bacteria capsules with a treatment and prevention effect on vaginitis. The lactic acid bacteria capsules capable of simultaneously adjusting dysbacteriosis of intestinal tracts and vagina and emphasizing treatment and prevention of the vaginitis are developed for achieving comprehensive effects. According to the technical scheme, excipient and lactic acid bacteria mixed bacteria powder are wrapped in the active lactic acid bacteria capsules with the treatment and prevention effect on vaginitis, and the lactic acid bacteria mixed bacteria powder comprises lactobacillus crispatus powder and other lactic acid bacteria subspecies powder with an effect of adjusting the intestinal flora. The active lactic acid bacteria capsules can be used for treating the vaginitis by adopting oral administration and intra-vaginal use; the oral lactobacillus can effectively improve the immunity of mucosa by stimulating the immune response of the intestinal mucosa, adjust the overall function state of a human body and well treat the vaginitis; and a large quantity of lactobacillus proliferated in the intestinal tract can inhibit growth of intestinal bacteria and reduce the risk of intestinal bacteria infection in vagina.

The invention discloses a probiotics-Chinese herbal medicine compound composition capable of loosening bowels to relieve constipation and application of the probiotics-Chinese herbal medicine compoundcomposition and belongs to the technical field of health-care foods. The composition comprises 13-15 kinds of lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, bifidobacterium lactis, lactobacillus acidophilus, bifidobacterium longum, lactobacillus reuteri, lactobacillus helveticus, lactobacillus fermentum, lactobacillus johnsonii, lactobacillus casei, lactobacillus crispatus, bifidobacterium breve, bifidobacterium bifidum and bifidobacterium infantis, 10-13 kinds of isomalto-oligosaccharide, inulin, lactitol, stachyose, fructo-oligosaccharide, xylo-oligosaccharide, Mannan-oligosaccharide, galacto-oligosaccharide, oat beta-glucan, glucan, soluble soybean polysaccharide, resistant dextrin and chitosan-oligosaccharide and 2-4 kinds of malts, fructus crataegi, blackplums and fermented soybeans. According to the probiotics-Chinese herbal medicine compound composition and the application thereof, probiotics, prebiotics and traditional Chinese medicine powder are compounded and can jointly promote intestinal canal health.

The invention discloses lactobacillus for producing lactic acid and H2O2 and an application of the lactobacillus. The lactobacillus is lactobacillus gasseri or lactobacillus crispatus, wherein the preservation number of the lactobacillus gasseri is CGMCC No. 15815 or CGMCC No. 15816; the preservation number of the lactobacillus crispatus is CGMCC No. 15813 or CGMCC No. 15814. The lactobacillus gasseri and lactobacillus crispatus provided by the invention have extremely strong lactic acid and H2O2 production ability, have good ability to adhere to vaginal epithelial cells, and can effectively inhibit reproduction of pathogenic bacteria like Gardner bacteria and Candida albicans in in-vivo and in-vitro experiments.

The invention relates to a lactobacillus expansible vaginal suppository as well as a preparation method and a detection method thereof. The expansible vaginal suppository comprises an expansion vector and a drug-containing matrix which coats the surface of the expansion vector and is formed by lactobacilli and a matrix, wherein the lactobacilli include lactobacillus plantarum, lactobacillus acidophilus, lactobacillus fermentum, lactobacillus salivarius, lactobacillus crispatus, lactobacillus casei, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus reuteri and lactobacillus bulgaricus, and the various lactobacilli can develop a significant synergistic effect together; and the drug-containing matrix further consists of an emulsifier, a sustained-release agent and carnauba wax. The lactobacillus expansible vaginal suppository provided by the invention, on the basis of seven unique advanced technologies, has effects of preventing effusion of medicine liquid, guaranteeing high stability, guaranteeing a lasting curative effect and the like.

The invention adopts fluorogenic quantitative PCR to detect dynamic changes of lactobacillus helveticus, lactobacillus crispatus, lactobacillus casei, lactobacillus delbrueckii and lactobacillus acidophilus in a vinegar grains community, thereby providing a technical support for research on other microbial communities.

The invention provides a strain. The strain is a Lactobacillus crispatus strain, and the preservation number of the strain is CGMCC No.6364. The invention also provides a use of the strain in the preparation of colpitis prevention and / or treatment drugs, a use of the strain in the preparation of vagina nursing articles, and a use of the strain in the preparation of external genitals health articles. By adopting the above technical scheme, the strain can effectively realize an antagonistic effect on a plurality of pathogenic bacteria. The strain has a high adherence ability to vaginal epithelial cell. The strain can well meet practical clinic application demands.

The present invention discloses Lactobacillus crispatus 262-1 and an inoculum comprising such strain and application thereof. The Lactobacillus crispatus 262-1 is a new strain of Lactobacillus genus and is preserved in the China General Microbiological Culture Collection Center with a preservation number of CGMCC No. 6469. The Lactobacillus crispatus 262-1 particularly is the dominant bacteria in the vagina, has good acid and H2O2 production capability, good adhesion to the vaginal epithelial cells and significant resistance to bacterial vaginosis and various vaginal infections, and is characterized by safety, non-toxicity, good stability and long term preservation. The present invention also relates to the use of the Lactobacillus crispatus 262-1 in the preparation of pharmaceuticals for preventing and / or treating gynecological diseases and its application in feminine care products such as medical instruments, disinfect products or cosmetics.

The invention discloses lactobacillus crispatus capable of preventing and / or treating helicobacter pylori infection, and belongs to the technical field of microorganisms and medicines. The invention provides the lactobacillus crispatus CCFM1118. The lactobacillus crispatus CCFM1118 can inhibit helicobacter pylori, and is specifically characterized in that: (1) the size of an inhibition zone of a lactobacillus crispatus CCFM1118 supernatant on helicobacter pylori can reach 13.14 mm; and (2) the lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of helicobacter pylori to AGScells; therefore, the lactobacillus crispatus CCFM1118 has a huge application prospect in the aspects of inhibiting helicobacter pylori (not aiming at the diagnosis and treatment of diseases) and preparing a helicobacter pylori inhibitor.

The invention discloses lactobacillus crispatus Lcr-MH175 for preventing and treating female urogenital tract infection. The preservation number of the Lcr-MH175 is CGMCC No. 15938. The lactobacilluscrispatus Lcr-MH175 provided by the invention has relatively strong antibacterial ability, can effectively inhibit growth of external pathogenic bacteria and pathogenic bacteria under other conditions, and also has a relatively strong adhesion effect on Hela cells so as to ensure the colonization of the strain on vaginal epithelium. The lactobacillus crispatus Lcr-MH175 provided by the invention has a certain application prospect in the aspect of urogenital tract infection prevention and treatment.

The invention discloses lactobacillus crispatus and application thereof. The perseveration number of the lactobacillus crispatus is as follows: CGMCC No.9388. The lactobacillus crispatus IMC-12 disclosed by the invention has relatively strong capacity of producing H2O2 and can be used for effectively inhibiting the growth of external pathogenic bacteria and other conditioned pathogenic bacteria and meanwhile, the lactobacillus cripatus has relatively strong adhesive attraction for vagina epithelial cells, so that the field planting of the vagina epithelial cell is guaranteed, and thus, the lactobacillus crispatus IMC-12 has certain application prospect in preventing and treating urogenital tract infection.

The invention relates to probiotics for preventing and treating female genital tract inflammation. The invention relates to lactobacillus for producing lactic acid and H2O2, a thallus lysis componentor a metabolite of the lactobacillus. The lactobacillus is selected from Lactobacillus crispatus, Lactobacillus gasseri or Lactobacillus salivarius, the preservation number of the Lactobacillus crispatus is CGMCC No. 19239, the preservation number of the Lactobacillus gasseri is CGMCC No. 19238, and the preservation number of the Lactobacillus salivarius is CGMCC No. 19236.

It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11 strain, KT-23 strain, or KT-25 strain bacterial cells and viable bacteria, dead bacteria, or a processed product of bacterial cells of other lactic acid bacteria belonging to the genus Lactobacillus, genus Bifidobacterium, genus Leuconostoc, genus Enterococcus, genus Pediococcus, etc. at a biomass-converted ratio of 99:1 to 50:50, preferably 99:1 to 75:25.

The invention provides an application of lactobacillus crispatus in treating or preventing rheumatoid arthritis or related diseases thereof, and also provides a pharmaceutical composition, a medicament, a food and a feed containing the lactobacillus crispatus. By providing the lactobacillus crispatus for animals, an anti-inflammatory effect can be effectively brought into play, the symptoms of rubefaction and swelling of joints can be effectively improved, and the symptoms of arthritis can be obviously relieved, so that the lactobacillus crispatus can be effectively used for treating or preventing the rheumatoid arthritis or the related diseases thereof.

The invention relates to the field of garbage disposal, in particular to a complex microbial agent and an application thereof in aerobic repair of landfill. The complex microbial agent contains an type-I complex microbial agent and / or a type-II complex microbial agent, wherein the type-I complex microbial agent is prepared from streptomyces badius, lactobacillus crispatus, bacillus megatherium, bacillus subtilis, bacillus licheniformis and active dry yeast; the type-II complex microbial agent is prepared from phanerochaete chrysosporium, bacillus cereus, paracoccus denitrificans, candida utilis and rhodococcus erythropolis. The complex microbial agent is an efficient microbial agent prepared by massive screening and compounding according to specificity of nature change of garbage components, environmental factors and pollutants in the aerobic repair process of the landfill. The two types of microbial agents are added selectively in the aerobic repair process of the landfill by stages,and by means of function specificity of the microbial agents, the aerobic repair operating effect of the landfill is enhanced, the treatment cycle is shortened, and the operating cost is reduced.

The invention provides a strain. The strain is a Lactobacillus crispatus strain, and the preservation number of the strain is CGMCC No.6363. The invention also provides a use of the strain in the preparation of colpitis prevention and / or treatment drugs, a use of the strain in the preparation of vagina nursing articles, and a use of the strain in the preparation of external genitals health articles. By adopting the above technical scheme, the strain can effectively realize an antagonistic effect on a plurality of pathogenic bacteria. The strain has a high adherence ability to vaginal epithelial cell. The strain can well meet practical clinic application demands.

The present invention relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 107 to 1010 CFU of lactobacilli. The invention also relates to a pharmaceutical composition including at least 100 mg of thiosulfate per gram, in combination with a Lactobacillus crispatus strain, and to its use in the treatment of urogenital infections such as vaginosis, candidosis and urinary tract infections.

The invention relates to the technical field of biology, in particular to a novel lactobacillus crispatus strain for preventing and / or treating genital tract flora disorder related diseases and application of the novel lactobacillus crispatus strain. In order to solve the technical problems of different degrees of side effects, high recurrence rate or large trauma and the like of the existing medicine for treating the genital tract flora disorder related diseases, the invention screens out a novel lactobacillus crispatus LG55-27 for preventing and / or treating the genital tract flora disorder related diseases, which can generate secretions such as lactic acid, hydrogen peroxide and the like, is used for inhibiting the growth of pathogenic bacteria of genital tract infection, is used for preventing and / or treating diseases related to genital tract flora disorder, particularly reduces the recurrence rate, has small toxic and side effects and lasting efficacy, and can be used as a dominantbacterial strain of the genital tract to increase the abundance, repair flora disorder and recover vaginal homeostasis.

The invention provides acid-resistant and bile-salt-resistant lactobacillus crispatus. The strain has the preservation name of lactobacillus crispatus ZLC020. The preservation number is CGMCC No.11531. The strain disclosed by the invention has excellent anti-bacterium performance; the obvious bacteriostatic effect is achieved on swine escherichia coli. The strain, the relevant strain and relevantfeed can improve the production performance of growth pig; the intestinal flora composition is improved; the body amino acid metabolism is promoted; good development and application prospects are realized.

The invention discloses a complex microbial inoculant for regulating the balance of gynecological flora. The complex microbial inoculant comprises Lactobacillus crispatus, Lactobacillus casei LC-N235and other acceptable drug excipients. Preferably, the Lactobacillus crispatus is Lactobacillus crispatus CGMCC 12743. The Lactobacillus casei LC-N235 is preserved in the China General MicrobiologicalCulture Collection Center, and the preservation number is CGMCC 18057. The complex microbial inoculant can be made into an oral liquid or fermented food, preferably fermented milk, fermented soymilk and the like.

The invention provides a probiotic corn leavening agent capable of increasing the content of L-lactic acid and the application of the probiotic corn leavening agent. The probiotic corn leavening agent is prepared from such components as lactobacillus delbrueckii, lactobacillus crispatus, pediococcus acidilactici, endomycopsis, saccharomyces uvarum, bacillus amyloliquefaciens, alpha-amylase, NH4CL accounting for 0.2%-0.25% of the mass of the leavening agent, Na2HPO4.12H2O accounting for 0.15%-0.2% of the mass of the leavening agent, and KH2PO4 accounting for 0.4%-0.5% of the mass of the leavening agent. The probiotic corn leavening agent is inoculated to corn in the mass ratio of 0.1%, and then the moisture content of materials is regulated to 40%, the fermentation temperature is controlled at 37 DEG C and the fermentation time is kept at 60 hours, and therefore, the content of the L-lactic acid in corn can be remarkably increased, the pH can be reduced and the palatability can be improved; besides, rapid breeding of a plurality of probiotics such as lactic acid bacteria, saccharomycetes and bacillus also can be promoted.

The invention discloses III-type bacteriocin Helveticin-M molecular from L. crispatus. The Helveticin-M molecular possesses antibacterial effect, and is a polypeptide selected from polypeptide (a), polypeptide (b), or polypeptide (c). The polypeptide (a) is obtained via coding of a DNA molecular with a base sequence represented by SEQ ID NO:1; the polypeptide (b) is obtained via coding of a DNA molecular with a base sequence represented by SEQ ID NO:2; and the polypeptide (a) is a derivative of polypeptide (b), is obtained via substitution, deletion, or addition of one or a plurality of amino acids, and possesses antibacterial activity. The invention also discloses a DNA molecular used for coding Helveticin-M molecular. The invention also discloses a preparation method of III-type bacteriocin Helveticin-M molecular, and applications of III-type bacteriocin Helveticin-M molecular, the DNA molecular, recombinant vectors, or host cells in food preservation bacteria inhibition and decomposition inhibition. The III-type bacteriocin Helveticin-M molecular possesses antibacterial activity, and can be used in food fresh keeping; heterologous expression can be realized; and the preparation method possesses guidance meaning in research and study on III-type bacteriocin.